• Erenumab (Aimovig): subcutaneous injection once a month

• Fremanezumab (Ajovy): subcutaneous injection once a month or once every three months

• Galcanezumab (Emgality): subcutaneous injection once a month

• Eptinezumab (Vyepti): intravenous injection every three months

• Ubrogepant (Ubrelvy): oral tablet, 50 mg or 100 mg as needed

• Rimegepant (Nurtec ODT): oral tablet, 75 mg as needed

• Atogepant (Qulipta): oral tablet, 100 mg as needed

• Vazegepant (Zeposia): oral tablet, 20 mg as needed

These drugs are all approved by the FDA for the prevention of migraine headaches. Ubrogepant and rimegepant are also approved for the acute treatment of migraine headaches.

It is important to note that CGRP inhibitors can have side effects, such as nausea, vomiting, and injection site reactions. It is also important to talk to your doctor about whether CGRP inhibitors are right for you, as they may not be appropriate for everyone.

Here are some additional information about CGRP inhibitors:

• CGRP is a protein that is released during migraine attacks. It is thought to play a role in the pain and inflammation that are associated with migraines.

• CGRP inhibitors work by blocking the binding of CGRP to its receptors. This prevents CGRP from signaling pain and inflammation.

• CGRP inhibitors are generally well-tolerated. The most common side effects are nausea, vomiting, and injection site reactions.

• CGRP inhibitors can be expensive. However, there are often financial assistance programs available to help people afford these medications.

If you are considering CGRP inhibitors, it is important to talk to your doctor about the risks and benefits. They can help you decide if CGRP inhibitors are right for you.